SEC-sourced researchBeta
ANIK
Anika Therapeutics, Inc.
Company comparison ↗
Data passport
- CIK
- 0000898437
- Exchange
- Nasdaq
- Business activity
- — · SIC 3841
- Financial inputs
- 5/6
- Filing date
- Mar 3, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 120,792,000.0000 | Mar 3, 2026 |
| December 2024 | 119,907,000.0000 | Mar 3, 2026 |
| December 2025 | 112,819,000.0000 | Mar 3, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 112,819,000.0000 | -10,880,000.0000 | 11,188,000.0000 | 190,270,000.0000 | — | Mar 3, 2026 |
| December 2024 | 119,907,000.0000 | -56,385,000.0000 | 5,403,000.0000 | 202,740,000.0000 | — | Mar 3, 2026 |
| December 2023 | 120,792,000.0000 | -82,667,000.0000 | -1,788,000.0000 | — | — | Mar 3, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $112.82M | December 2025 | Mar 3, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $119.91M | December 2024 | Mar 3, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$10.88M | December 2025 | Mar 3, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $11.19M | December 2025 | Mar 3, 2026 | 10-K |
| Total assetsAssets | $190.27M | December 2025 | Mar 3, 2026 | 10-K |
| Total liabilities | — | — | — | — |